Global Biologics and Biosimilars Market Growth (Status and Outlook) 2025-2031

Global Biologics and Biosimilars Market Growth (Status and Outlook) 2025-2031

The global Biologics and Biosimilars market size is predicted to grow from US$ 431720 million in 2025 to US$ 724220 million in 2031; it is expected to grow at a CAGR of 9.0% from 2025 to 2031.

Biologics are very specific, highly effective medicines made in living cells, and historically this was often an animal. Biologics include hormones, cytokines, growth factors, vaccines, gene and cellular therapies, fusion proteins, insulin, interferon, and monoclonal antibody (mAb) products.

A biosimilar (also known as follow-on biologic or subsequent entry biologic) is a biologic medical product that is almost an identical copy of an original product that manufactured by a different company. Biosimilar are officially approved versions of original innovator products and can manufactured when the original products patent expires. Reference to the innovator product is an integral component of the approval.

Global key biologics and biosimilars manufacturers include Johnson & Johnson, Pfizer, Roche, Amgen, AbbVie, and others. The top five manufacturers together account for approximately 50% of the market share, with the largest manufacturer being Pfizer with over 20% share. In terms of product categories, monoclonal antibodies are the largest segment with a market share of 43%, followed by vaccines with a 30% share. In terms of applications, hospitals are the top application area, with about 85% of the market share.

LPI (LP Information)' newest research report, the “Biologics and Biosimilars Industry Forecast” looks at past sales and reviews total world Biologics and Biosimilars sales in 2024, providing a comprehensive analysis by region and market sector of projected Biologics and Biosimilars sales for 2025 through 2031. With Biologics and Biosimilars sales broken down by region, market sector and sub-sector, this report provides a detailed analysis in US$ millions of the world Biologics and Biosimilars industry.

This Insight Report provides a comprehensive analysis of the global Biologics and Biosimilars landscape and highlights key trends related to product segmentation, company formation, revenue, and market share, latest development, and M&A activity. This report also analyses the strategies of leading global companies with a focus on Biologics and Biosimilars portfolios and capabilities, market entry strategies, market positions, and geographic footprints, to better understand these firms’ unique position in an accelerating global Biologics and Biosimilars market.

This Insight Report evaluates the key market trends, drivers, and affecting factors shaping the global outlook for Biologics and Biosimilars and breaks down the forecast by Type, by Application, geography, and market size to highlight emerging pockets of opportunity. With a transparent methodology based on hundreds of bottom-up qualitative and quantitative market inputs, this study forecast offers a highly nuanced view of the current state and future trajectory in the global Biologics and Biosimilars.

This report presents a comprehensive overview, market shares, and growth opportunities of Biologics and Biosimilars market by product type, application, key players and key regions and countries.

Segmentation by Type:
Monoclonal Antibodies
Interferon
Insulin
Vaccines
Others

Segmentation by Application:
Hospital
Retail Pharmacy
Other

This report also splits the market by region:
Americas
United States
Canada
Mexico
Brazil
APAC
China
Japan
Korea
Southeast Asia
India
Australia
Europe
Germany
France
UK
Italy
Russia
Middle East & Africa
Egypt
South Africa
Israel
Turkey
GCC Countries

The below companies that are profiled have been selected based on inputs gathered from primary experts and analyzing the company's coverage, product portfolio, its market penetration.
Roche
Amgen
AbbVie
Sanofi
Johnson & Johnson
Pfizer
Novo Nordisk
Eli Lilly
Novartis
Merck
Biogen
Celltrion
Sobi
3SBIO
Changchun High Tech
Kanghong Pharma
Innovent Biologics
Gan&Lee
Tonghua Dongbao
United Laboratory

Please note: The report will take approximately 2 business days to prepare and deliver.